<DOC>
	<DOCNO>NCT00048321</DOCNO>
	<brief_summary>ISIS 104838 antisense oligonucleotide drug reduces production specific protein call tumor necrosis factor ( TNF-alpha ) , substance contributes joint pain swell rheumatoid arthritis . ISIS 104838 work block TNF-alpha messenger RNA , `` instruction '' molecule require production TNF-alpha protein . This trial ass safety efficacy ISIS 1048383 subcutaneous injection , administer 3 different dose regimen 3 month , versus placebo . Approximately 160 TNF-alpha inhibitor-na√Øve rheumatoid arthritis patient evaluate 32 site U.S. Canada .</brief_summary>
	<brief_title>ISIS 104838 , Inhibitor Tumor Necrosis Factor , Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion Criteria 1 . Age &gt; /= 18 year . 2 . Rheumatoid arthritis &gt; /= 6 month . 3 . Active disease define &gt; /= 6 swollen &gt; /= 9 tender joint , AND abnormal Creactive protein Westergren Erythrocyte Sedimentation Rate lab test , OR Morning Stiffness &gt; /= 1 hour . 4 . Use least one DMARD , ability discontinue current DMARD . Exclusion Criteria 1 . Onset rheumatoid arthritis 16th birthday . 2 . Wheelchair bedbound functional level . 3 . No previous infliximab etanercept treatment , investigational therapy ( placebo ) TNFalpha inhibitor . 4 . Prednisone &gt; 10 mg per day one nonsteroidal antiinflammatory drug . 5 . Patients active infection , history tuberculosis , multiple sclerosis , poorly control medical illness , malignancy within last 5 year . 6 . Patients require intravenous heparin therapy history bleeding problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>